Disclosures for "A First-in-Human Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN293, an Investigational Inhibitor of KCNK13 Targeting NLRP3-Mediated Neuroinflammation"
-
Dr. Vaidya has received personal compensation for serving as an employee of Cerevance. Dr. Vaidya has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Dickson has received personal compensation for serving as an employee of Cerevance.
-
Dr. Tolando has nothing to disclose.
-
Dr. Scholl has nothing to disclose.
-
Mrs. Charles has received personal compensation for serving as an employee of Cerevance Inc..
-
Dr. Ossola has received personal compensation for serving as an employee of Cervance.
-
Dr. Matthews has nothing to disclose.
-
Dr. Scott has received personal compensation for serving as an employee of GS Drug Development Sciences Ltd. An immediate family member of Dr. Scott has received personal compensation for serving as an employee of GS Drug Development Sciences Ltd.
-
Dr. Bexon has received personal compensation for serving as an employee of BexonClinical Consulting LLC.
-
Miss Castricum has nothing to disclose.
-
Dr. Kremer has nothing to disclose.
-
Dr. Dawson has received personal compensation for serving as an employee of Cerevance Ltd. Dr. Dawson has stock in Cerevance Ltd.
-
Dr. Carlton has received personal compensation for serving as an employee of Cerevance. Dr. Carlton has stock in Cerevance.
-
Dr. Brice has received personal compensation for serving as an employee of Cerevance.